Check Out This $IVOB Analysis By StocksHaven.com

August 23rd, 2009 at 6:43 pm Posted by The Dean

The Dean has a VERY IMPORTANT HOMEWORK ASSIGNMENT for all CollegeStock students this evening. It’s a well written $IVOB analysis by StocksHaven.com writer Michael Vlaicu called ‘Giving Birth to a Profitable Company (OTC: IVOB)‘. The full article is available HERE.

Eric Sebastien is an entrepreneur with solid investment experience totalling fifteen years, and specializes in the small cap bio-tech field. Eric is a 37 year old, French Canadian, IT engineer, well on his way to starting his own company which can be found at, www.klinkoo.com. He is presently in talks with a Venture Capital firm.

Below you’ll find one of the more interesting sections, ‘For World Market’, which calculates $IVOB’s earnings potential assuming a 5% market penetration:

For World Market

“We are thrilled by the positive response from distributors to assist INVO Bioscience in launching the INVO procedure in South America. The availability of the INVO procedure in both stand-alone centers and existing IVF centers reaffirms that this breakthrough does not compete with IVF, but instead is a new option that will greatly increase access to treatment to the 150 million infertile couples worldwide,” said Karloff.

We can once again apply the simple formula to do the calculations for the entire world market: take the number of estimated infertile couples potentially treated with INVOcell (5%), multiply by the average number of attempts which is 3125$ to 300$) lets once again take the median so 212.50$. and the average price sale to distributors in Europe and U.S (

We are now left with 5% of 150,000,000 = 7,500,000 couples

At an average of 3 attempts per couple = (7,500,000) X (3 X $212.50) = $4,781,250,000

These are not your eyes deceiving you, that is roughly more than $4 billion in revenue.

In fact, these numbers are quite conservative, with only 5% of the market, we don’t incur much risk. Moreover, the first investor of Invo stated few months ago that the market is estimated to be $66B dollars .

“With an addressable global market in excess of $66 billion, limited competition, massive profit margins and a management team that is second to none, Invo Bioscience is the perfect storm in regards to an investment opportunity,” said Christopher Esposito of Lionshare.

Presently, there is a market cap of $15 M, well let’s say that’s a really beautiful gift at this price, until investors realize what a gem this company is.

The Dean is traveling to DUBAI, UNITED ARAB EMIRATES in November 2009 to participate in the Middle East’s Annual Infertility Conference and to listen to $IVOB CEO Katie Karloff address the world media by STORM!